scholarly journals Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi‐parametric flow cytometry method

2019 ◽  
Vol 94 (4) ◽  
pp. 424-430 ◽  
Author(s):  
Surbhi Sidana ◽  
Dragan Jevremovic ◽  
Rhett P. Ketterling ◽  
Nidhi Tandon ◽  
Angela Dispenzieri ◽  
...  
2018 ◽  
Author(s):  
Surbhi Sidana ◽  
Nidhi Tandon ◽  
Dragan Jevremovic ◽  
Rhett P. Ketterling ◽  
Angela Dispenzieri ◽  
...  

2018 ◽  
Vol 8 (1) ◽  
pp. e621-e621 ◽  
Author(s):  
T Jelinek ◽  
R Bezdekova ◽  
M Zatopkova ◽  
L Burgos ◽  
M Simicek ◽  
...  

2017 ◽  
Vol 33 (3) ◽  
pp. 303-315 ◽  
Author(s):  
Gaurav Chatterjee ◽  
Sumeet Gujral ◽  
Papagudi G. Subramanian ◽  
Prashant R. Tembhare

2020 ◽  
Vol 99 (11) ◽  
pp. 2599-2609
Author(s):  
Svitlana Demyanets ◽  
Alexandra Kaider ◽  
Ingrid Simonitsch-Klupp ◽  
Günther Bayer ◽  
Almira Subasic ◽  
...  

Abstract Methods to estimate bone marrow plasma cells (BMPC) basically include histopathology, cytomorphology, and flow cytometry. The present study compares the outcomes of these methods with special focus on the impact of BMPC-specific characteristics on their recovery by either method. Laboratory reports of diagnostic samples from 238 consecutive patients with suspected or known plasma cell disease were retrospectively analyzed. The median (IQR) proportion of BMPC was 30.0% (15.0–70.0%) by histological review (hBMPC), 7.0% (2.0–16.0%) by smear review (sBMPC), and 3.0% (0.8–10.0%) by flow cytometry (fBMPC). The disparity of results between core biopsy and aspirate smear was enhanced in case of poor quality of the smear, increased BM fiber content, higher grade cell atypia, expression of CD56 (all P < 0.0001), the number of cytogenetic aberrations (P = 0.0002), and abnormalities of the MYC gene (P = 0.0002). Conversely, expression of CD19 and a non-clonal plasma cell phenotype were associated with a lower difference between hBMPC and sBMPC (both P < 0.0001). The disparity between the percentages of sBMPC and fBMPC was associated with the quality of the smear (P = 0.0007) and expression of CD56 (P < 0.0001). Our results suggest that the recovery of BMPC in aspirate specimens not only is a matter of sampling quality but also depends on biological cell properties. Aspiration failure due to malignant type features of BMPC may lead to misclassification of plasma cell disorders and represent a bias for the detection of minimal residual disease after therapy.


2017 ◽  
Vol 7 (10) ◽  
pp. e617-e617 ◽  
Author(s):  
T Jelinek ◽  
R Bezdekova ◽  
M Zatopkova ◽  
L Burgos ◽  
M Simicek ◽  
...  

Abstract Multiparameter flow cytometry (MFC) has become standard in the management of patients with plasma cell (PC) dyscrasias, and could be considered mandatory in specific areas of routine clinical practice. It plays a significant role during the differential diagnostic work-up because of its fast and conclusive readout of PC clonality, and simultaneously provides prognostic information in most monoclonal gammopathies. Recent advances in the treatment and outcomes of multiple myeloma led to the implementation of new response criteria, including minimal residual disease (MRD) status as one of the most relevant clinical endpoints with the potential to act as surrogate for survival. Recent technical progress led to the development of next-generation flow (NGF) cytometry that represents a validated, highly sensitive, cost-effective and widely available technique for standardized MRD evaluation, which also could be used for the detection of circulating tumor cells. Here we review current applications of MFC and NGF in most PC disorders including the less frequent solitary plasmocytoma, light-chain amyloidosis or Waldenström macroglobulinemia.


2016 ◽  
Vol 92 (2) ◽  
pp. 145-152 ◽  
Author(s):  
Katharina Lisenko ◽  
Stefan Schönland ◽  
Ute Hegenbart ◽  
Katrin Wallenwein ◽  
Ute Braun ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document